"The launch of VereFlu marks a substantial breakthrough in enabling rapid identification of the infectious agent to limit the spread of the disease and speed patients' treatment," said Gian Luca Bertino, Corporate VP and General Manager of ST's Computer Peripherals Group. "The combination of Veredus' diagnostic know-how with ST's microfluidic lab-on-chip technology has bred the market's first solution that detects multiple flu viruses at the point of need in a fraction of the time, cost, and complexity of conventional diagnostic systems."
A miniature laboratory on a chip, ST's In-Check platform allows users to accurately and reliably process and analyze minute patient samples -- human blood, serum or respiratory swabs -- on a single disposable thumbnail-sized chip. This approach reduces the time and complexity, as well as the risk of cross-contamination inherent in conventional analysis methods.
Encouraged by the success of the VereFlu project, STMicroelectronics and Veredus Laboratories have set up a joint lab, where experts from both companies will work together on the development of new biomedical applications based on ST's In-Check lab-on-chip platform. Future application areas of interest include other infectious diseases, oncology and heart-disease markers. The new ST/Veredus biomedical laboratory, called the Bio-Application Lab, is located at the Science Park in Singapore and will be managed by Dr. Rosemary Tan, CEO of Veredus.
About Veredus Laboratories Pte Ltd
Founded in 2003, Veredus Laboratories Pte Ltd is a privately held,
medical diagnostics company engaged in the development, co
'/>"/>
| SOURCE STMicroelectronics Copyright©2008 PR Newswire. All rights reserved |